Circulating Antibodies to Carcinoembryonic Antigen Related to Improved Recurrence-Free Survival of Patients with Colorectal Carcinoma

Wu, Xiaojun; Fang, Yuan; Lin, Jie; Lu, Zhong-Ming; Li, Liren; Chen, G.; Ding, Pei-Rong; Kong, Ling Heng; Pan, Zhizhong; Wan, De Sen

doi:10.1177/147323001103900317

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also collected multiple autoantibodies in 42 different combinations for CRC (Table 2). 11-83 The research was mainly undertaken in China (n = 20) and the USA (n = 12), with the remainder in Japan, Germany, Spain, and elsewher...…”

Section: Resultsmentioning

confidence: 99%

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Wang

Zhou

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

Colorectal cancer is a very common cancer worldwide. Serum tumor-associated autoantibodies (TAAbs), especially the anti-p53 autoantibody, may be promising biomarkers to detect early-stage colorectal cancer. This study aimed to identify all known autoantibodies and their value in colorectal cancer diagnosis, as well as exploring the underlying connections and mechanisms through a bioinformatics analysis. Databases were used to select available articles of TAAbs in colorectal cancer. In a meta-analysis of the anti-p53 autoantibody, the diagnostic odds ratio and area under the curve (AUC) of the summary receiver-operating characteristic (SROC) curve were calculated using Stata 12.0 and Meta-Disc 1.4. We identified 73 articles including 199 single autoantibodies and 42 multiple autoantibodies. The maximum value of Youden's index was 0.76, combining c-MYC, p53, cyclin B1, p62, Koc, IMP1, and survivin. The diagnostic odds ratio for anti-p53 autoantibody at all stages was 10.86 (95% CI 8.40, 14.06) with low heterogeneity (I 2 = 40.3%) and the AUC of the SROC curve was 0.82. For the anti-p53 autoantibody in early-stage colorectal cancer, the diagnostic odds ratio was 4.82 (95% CI 2.95, 7.87) with heterogeneity (I 2 = 7.9%) and the AUC of the SROC curve was 0.72. Eighty-seven autoantibodies were selected for bioinformatics analyses. We found that the most enriched functional terms and protein-protein interactions may relate to the mechanism of autoantibody generation. In summary, our study summarized the diagnostic value of TAAbs in colorectal cancer, either as single molecules or in combination. Bioinformatics analyses may be a new approach to explore the mechanism of autoantibody generation.

show abstract

Section: Resultsmentioning

confidence: 99%

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Wang

Zhou

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…In addition, the reference lists of review articles and related articles were manually screened to identify additional studies. Finally, a total of 80 articles involving 145 specific tumour‐associated autoantibodies detected in patients with CRC were selected (Table ) . Anti‐p53 antibody was the most commonly studied autoantibody, followed by MUC1, CEA, c‐myc, survivin, HDAC5, p62, ANXA4, koc, NY‐CO‐16, NY‐ESO‐1, RPH3AL, cyclin B, Imp1, IMPDH2 and MAGEA3.…”

Section: Resultsmentioning

confidence: 99%

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Serum autoantibodies against tumour-associated antigens are promising biomarkers for diagnosis of cancer. This review summarizes the available evidence pertaining to the diagnostic potential of autoantibodies studied in the context of colorectal cancer (CRC). A systematic literature search was conducted in three databases (PubMed, Cochrane Library and Embase). Data pertaining to a total of 145 autoantibodies published in 80 articles were reviewed. Of these, anti-p53 antibody was the most commonly studied autoantibody; thus, we performed a meta-analysis on anti-p53 antibody in 24 articles. According to the cut-off values used to determine positivity for anti-p53 antibody, we divided the included studies into five groups. Owing to the presence of threshold effect in groups 4 and 5 and non-threshold effect in groups 1 and 2, pooled analysis focused on group 3 using a fixed-effects model (Mantel-Haenszel). Group 3, determining the cut-off value based on the value of p53 antibody titre index, was comprised of five articles including 733 patients with CRC and 172 controls (126 healthy individuals and 46 benign diseases). The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and summary area under the receiver operating characteristic curves were 0. 21, 0.99, 12.26, 0.80, 15.46 and 0.87, respectively. Serum anti-p53 autoantibody may potentially help distinguish CRC from healthy controls or benign diseases; however, it should be used in combination with other indicators due to the low sensitivity. Our study provides insights for further exploration of the optimal combination of different tumour-associated antigens or autoantibodies for diagnosis of CRC.

show abstract

“…The most frequently used test is to assay carcinoembryonic antigen (CEA) in human serum 13 – 15 . A large number of commercially available products utilizing different technologies, such as sandwiched enzyme-linked immunosorbent assay (ELISA) 16 , 17 , immunonephelometry 18 , 19 , and chemiluminometric immunoassay (CLIA) etc. 20 , 21 , have been widely applied in clinics.…”

Section: Introductionmentioning

confidence: 99%

Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction

Wei

Lee

Tseng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Immunomagnetic reduction (IMR) is a method to assay biomolecules by utilizing antibody functionalized magnetic nanoparticles. For clinical validation, important analytic performances of assaying carcinoembryonic antigen (CEA) using IMR are characterized. Furthermore, IMR is applied to assay carcinoembryonic antigen (CEA) in human serum for clinical validation. A total of 118 healthy controls and 79 patients with colorectal cancer (CRC) are recruited in this study. For comparison, assays using chemiluminometric immunoassay (CLIA) are also done for quantizing CEA in these serum samples. The results reveal a high correlation in terms of serum CEA concentration detected via IMR and CLIA is found (r = 0.963). However, IMR shows higher clinical sensitivity and specificity than those of CLIA. Moreover, the rate of false positives for smoking subjects is clearly reduced through the use of IMR. All the results demonstrate IMR is a promising alternative assay for serum CEA to diagnose CRC.

show abstract

Circulating Antibodies to Carcinoembryonic Antigen Related to Improved Recurrence-Free Survival of Patients with Colorectal Carcinoma

Cited by 7 publications

References 23 publications

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction

Contact Info

Product

Resources

About